Diagnosis, prevention, and management of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in organ transplant recipients

Current Opinion in Organ Transplantation

Volumn 8, Issue 4, 2003, Pages 276-282

  Nowalk, Andrew J ^a   Green, Michael ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic T lymphocyte; Epstein Barr virus; Posttransplant lymphoproliferative disease; Rituximab

Indexed keywords

EID: 18244396418     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200312000-00004     Document Type: Review

References (39)

1. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, et al.: Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992, 166:986-994.
2. Savoie A, Perpete C, Carpentier L, et al.: Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994, 83:2715-2722.
3. Stevens SJ, Verschuuren EA, Verkuujlen SA, et al.: Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma. 2002, 43:831-840.
4. Leung E, Shenton BK, Jackson G, et al.: Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood. J Immunol Methods 2002, 270:259-267.
5. Wadowsky RM, Laus S, Green M, et al.: Comparison of Epstein-Barr virus DNA load measured in whole blood and plasma by Taqman PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003, in press.
6. Green M, Webber SA: EBV load monitoring: unanswered questions. Am J Transplant 2002, 2:894-895.
7. Tanner JE, Alfieri C: The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001, 3:60-69.
8. Smets F, Latinne D, Bazin H, et al.: Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002, 73:1603-1610.
9. Qu L, Green M, Webber S, et al.: Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 2000, 182:1013-1021.
10. Rose C, Green M, Webber S, et al.: Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol 2002, 40:2533-2544.
11. Gutierrez MI, Ibrahim MM, Dale JK, et al.: Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus. J Natl Cancer Inst 2002, 94:1757-1763.
12. Porcu P, Eisenbeis CF, Pelletier RP, et al.: Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood 2002, 100:2341-2348.
13. Rowe DT, Webber S, Schauer EM, et al.: Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001, 3:79-87.
14. Straathof KC, Savoldo B, Heslop HE, et al.: Immunotherapy for posttransplant lymphoproliferative disease. Br J Haematol 2002, 118:728-740.
15. Tzakis AG: Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation. Transpl Infect Dis 2001, 3:35-39.
16. Press OW, Eary JF, Appelbaum FR, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219-1224.
17. Fischer A, Blanche S, Le Bidois J, et al.: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991, 324:1451-1456.
18. Oertel SH, Anagnostopoulos I, Bechstein WO, et al.: Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000, 69:430-432.
19. Serinet MO, Jacquemin E, Habes D, et al.: Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 2002, 34:389-393.
20. Berney T, Delis S, Kato T, et al.: Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002, 74:1000-1006.
21. Verschuuren EA, Stevens SJ, van Imhoff GW, et al.: Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002, 73:100-104.
22. Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol 1999, 26:74-78.
23. Winkler U, Jensen M, Manzke O, et al.: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999, 94:2217-2224.
24. Roskrow MA, Suzuki N, Gan Y, et al.: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998, 91:2925-2934.
25. Liu Z, Savoldo B, Huls H, et al.: Epstein-Barr virus (EBV)-specific cytotoxic lymphocytes for the prevention and treatment of EBV-associated posttransplant lymphomas. Recent Results Cancer Res 2002, 159:123-133.
26. Rooney CM, Smith CA, Ng CY, et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555.
27. Haque T, Wilkie GM, Taylor C, et al.: Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360:436-442.
28. Sun Q, Burton R, Reddy V, et al.: Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBVrelated lymphoma. Br J Haematol 2002, 118:799-808.
29. Subklewe M: Dendritic cells for the induction of EBV immunity. Recent Results Cancer Res 2002, 159:38-43.
30. Emanuel DJ, Lucas KG, Mallory GB Jr, et al.: Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997, 63:1691-1694.
31. Watts RG, Hilliard LM, Berkow RL: Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation. J Pediatr Hematol Oncol 2002, 24:622-626.
32. Gross TG: Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Results Cancer Res 2002, 159:96-103.
33. Khanna R, Moss DJ, Burrows SR: Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999, 170:49-64.
34. McDiarmid SV, Jordan S, Kim GS, et al.: Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998, 66:1604-1611.
35. Holmes RD, Orban-Eller K, Karrer FR, et al.: Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002, 74:367-372.
36. Shroff R, Trompeter R, Cubitt D, et al.: Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol 2002, 17:770-775.
37. Timms JM, Bell A, Flavell JR, et al.: Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBVpositive Hodgkin's lymphoma. Lancet 2003, 361:217-223.
38. Rooney CM: New insights into EBV-associated post-transplant lymphoproliferative disease. Lancet 2003, 361:192-193.
39. Johannessen I, Perera SM, Gallagher A, et al.: Expansion in scid mice of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease biopsy material. J Gen Virol 2002, 83:173-178.